New tools can propel research in lysosomal storage diseases

被引:0
|
作者
Hertz, Ellen [1 ]
Glasstetter, Logan M. [1 ]
Chen, Yu [1 ]
Sidransky, Ellen [1 ,2 ]
机构
[1] Natl Human Genome Res Inst, NIH, Med Genet Branch, Mol Neurogenet Sect, Bethesda, MD 20894 USA
[2] Natl Human Genome Res Inst, NIH, Med Genet Branch, Bld 35A Room 1E623, 35A Convent Dr, Bethesda, MD 20892 USA
关键词
Lysosomal storage diseases; Lysosome; Induced pluripotent stem cells (iPSC); CRISPR; Lyso-IP; CLN3; REVEALS; MTORC1;
D O I
10.1016/j.ymgme.2023.107729
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Historically, the clinical manifestations of lysosomal storage diseases offered an early glimpse into the essential digestive functions of the lysosome. However, it was only recently that the more subtle role of this organelle in the dynamic regulation of multiple cellular processes was appreciated. With the need for precise interrogation of lysosomal interplay in health and disease comes the demand for more sophisticated functional tools. This demand has recently been met with 1) induced pluripotent stem cell-derived models that recapitulate the disease phenotype in vitro, 2) methods for lysosome affinity purification coupled with downstream omics analysis that provide a high-resolution snapshot of lysosomal alterations, and 3) gene editing and CRISPR/Cas9-based functional genomic strategies that enable screening for genetic modifiers of the disease phenotype. These emerging methods have garnered much interest in the field of neurodegeneration, and their use in the field of metabolic disorders is now also steadily gaining momentum. Looking forward, these robust tools should accelerate basic science efforts to understand lysosomal dysfunction distal to substrate accumulation and provide translational opportunities to identify disease-modifying therapies.
引用
收藏
页数:4
相关论文
共 50 条
  • [41] NEURONOPATHIC LYSOSOMAL STORAGE DISEASES: CLINICAL AND PATHOLOGIC FINDINGS
    Prada, Carlos E.
    Grabowski, Gregory A.
    DEVELOPMENTAL DISABILITIES RESEARCH REVIEWS, 2013, 17 (3-4) : 226 - 246
  • [42] Lysosomal Storage Diseases: Is Impaired Apoptosis a Pathogenic Mechanism?
    Claudine Tardy
    Nathalie Andrieu-Abadie
    Robert Salvayre
    Thierry Levade
    Neurochemical Research, 2004, 29 : 871 - 880
  • [43] Secondary Biochemical and Morphological Consequences in Lysosomal Storage Diseases
    Alroy, J.
    Garganta, C.
    Wiederschain, G.
    BIOCHEMISTRY-MOSCOW, 2014, 79 (07) : 619 - 636
  • [44] Diagnostics of lysosomal storage diseases by mass spectrometry: a review
    Pancik, Filip
    Pakanova, Zuzana
    Kveton, Filip
    Barath, Peter
    CHEMICAL PAPERS, 2022, 76 (07) : 3995 - 4004
  • [45] Hepatomegaly and Splenomegaly: An Approach to the Diagnosis of Lysosomal Storage Diseases
    Jerves Serrano, Teodoro
    Gold, Jessica
    Cooper, James A.
    Church, Heather J.
    Tylee, Karen L.
    Wu, Hoi Yee
    Kim, Sun Young
    Stepien, Karolina M.
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (05)
  • [46] Diagnostics of lysosomal storage diseases by mass spectrometry: a review
    Filip Pančík
    Zuzana Pakanová
    Filip Květoň
    Peter Baráth
    Chemical Papers, 2022, 76 : 3995 - 4004
  • [47] Secondary biochemical and morphological consequences in lysosomal storage diseases
    J. Alroy
    C. Garganta
    G. Wiederschain
    Biochemistry (Moscow), 2014, 79 : 619 - 636
  • [48] A Phenotypic Compound Screening Assay for Lysosomal Storage Diseases
    Xu, Miao
    Liu, Ke
    Swaroop, Manju
    Sun, Wei
    Dehdashti, Seameen J.
    McKew, John C.
    Zheng, Wei
    JOURNAL OF BIOMOLECULAR SCREENING, 2014, 19 (01) : 168 - 175
  • [49] Sphingolipid lysosomal storage diseases: from bench to bedside
    Abed Rabbo, Muna
    Khodour, Yara
    Kaguni, Laurie S.
    Stiban, Johnny
    LIPIDS IN HEALTH AND DISEASE, 2021, 20 (01)
  • [50] Sphingolipid lysosomal storage diseases: from bench to bedside
    Muna Abed Rabbo
    Yara Khodour
    Laurie S. Kaguni
    Johnny Stiban
    Lipids in Health and Disease, 20